Our findings demonstrate that increased galectin-3 in microglia contributes to inflammation and disease progression, while targeting galectin-3 by genetic or pharmacological approaches ameliorates light-induced retinal degeneration. This evidence concerns the gene LGALS3 and retinal degeneration.